ライフサイエンスコーパス: DNA antibody

1 hromes and a monoclonal anti-double-stranded DNA antibody.

2 nic for the heavy chain of a pathogenic anti-DNA antibody.

3 nic for the heavy chain of a pathogenic anti-DNA antibody.

4 on of hormones, and anti-double-stranded (ds)DNA antibody.

5 spital because of a high serum level of anti-DNA antibody.

6 ce transgenic for the heavy chain of an anti-DNA antibody.

7 is recognized by both murine and human anti-DNA antibodies.

8 diotypic antibodies and anti-single-stranded DNA antibodies.

9 mplementemia, and/or elevated levels of anti-DNA antibodies.

10 , which is expressed on anti-double-stranded-DNA antibodies.

11 is, deforming arthropathy and increased anti-DNA antibodies.

12 ansgenic mice whose transgenes code for anti-DNA antibodies.

13 uate predictors of the pathogenicity of anti-DNA antibodies.

14 esearch and point-of-care monitoring of anti-DNA antibodies.

15 uding seroconversion of anti-double-stranded DNA antibodies.

16 tinuclear antibodies or anti-double-stranded DNA antibodies.

17 terized by the production of double-stranded DNA antibodies.

18 icient 3H9 mice spontaneously generated anti-DNA antibodies.

19 ) treated with pathogenic, noncomplexed anti-DNA antibodies.

20 DNA-derived peptides and peptides from anti-DNA antibodies.

21 e presence of serum anti-double-stranded (ds)DNA antibodies (Abs), whereas nonautoimmune individuals

22 is the presence of anti-double-stranded (ds)DNA antibodies (Abs).

23 orbent assay plates was used to measure anti-DNA antibody activity.

24 itis, and patients with anti-double-stranded DNA antibodies (adjusted HR approximately 2.0 for each o

25 ipients caused a lupuslike disease with anti-DNA antibodies, an immune complex glomerulonephritis and

26 Both human monoclonal anti-DNA antibodies and antibodies affinity purified from the

27 bromocriptine led to reduced titers of anti-DNA antibodies and diminished IgG deposition in kidneys

28 ly activated the production of antichromatin/DNA antibodies and dramatically accelerated renal diseas

29 nal because it helps B cells to produce anti-DNA antibodies and express more CD80 (B7-1) on their sur

30 oped systemic autoimmunity, characterized by DNA antibodies and immune complex glomerulonephritis.

31 These mice develop high-titer anti-DNA antibodies and immune complex-mediated nephritis and

32 ion (PBSCT) prevented the production of anti-DNA antibodies and the development of lupus nephritis in

33 a significant change in anti-double-stranded DNA antibody and complement levels.

34 is demonstrated by single-step labelling of DNA, antibodies and proteins, as well as applications in

35 ccurrence of anti-AIM2, anti-IFI16, and anti-DNA antibodies, and higher clinical measures of disease

36 ce of pathogenic anti-dsDNA (double-stranded DNA) antibodies, and provided spontaneous help for autoa

37 eived injections of radiolabeled murine anti-DNA antibody, antibody with no DNA binding capability, a

38 We found that high-affinity anti-DNA antibodies are a major component of the intrathecal

39 Anti-DNA antibodies are associated with glomerulonephritis in

40 Anti-double-stranded (ds) DNA antibodies are not only an important diagnostic mark

41 Anti-DNA antibodies are produced transiently, mainly during p

42 Anti-DNA antibodies are regulated in normal individuals but a

43 Lupus-associated IgG anti-double-stranded DNA antibodies are thought to be pathogenic in the kidne

44 gnificant gene up-regulation induced by anti-DNA antibodies as determined by microarray analysis was

45 mplex generation, using anti-double-stranded DNA antibody as a biomarker; and (iii) preservation of k

46 tly reduced the renal deposition of the anti-DNA antibody at 48 h (1.53%, P < 0.00001) and at 7-8 d (

47 rbB2 gene product, was recognized by an anti-DNA antibody, B3, and importantly by two classical DNA-b

48 ytes including, but not limited to, glucose, DNA, antibodies, bacteria and viruses.

49 body could provide a mechanism by which anti-DNA antibodies bind diverse host ligands, and thereby co

50 g recent reports that pathogenic murine anti-DNA antibodies bind to alpha-actinin, it was obviously o

51 ite-specific, well-defined and plasma-stable DNA-antibody bioconjugates for biological applications.

52 The homogeneity of the prepared DNA-antibody bioconjugates was confirmed by a new LC-MS

53 report a new platform for the preparation of DNA-antibody bioconjugates with a simple benzoylacrylic

54 on of IgM, IgG, and IgA, as well as IgM anti-DNA antibodies, but was not necessary for B cell stimula

55 Levels of anti-DNA antibodies can fluctuate widely, unlike those of ant

56 tibodies, deposition of anti-double-stranded DNA antibody complexes, complement activation, and immun

57 t the assembly of nanosensors prepared using DNA-antibody conjugates, which combine capture and detec

58 n and the generation of anti-double-stranded-DNA antibodies, critically aggravating atherosclerosis l

59 It has been shown that anti-DNA antibodies cross-react with bacterial polysaccharide

60 Levels of anti-double-stranded DNA antibodies decreased by a median of 47% in patients

61 boration, production of anti-double-stranded DNA antibodies, deposition of anti-double-stranded DNA a

62 A unique subset of anti-DNA antibodies enters living cells, interacts with DNase

63 The anti-DNA antibody fragment 3E10 Fv has received attention as

64 s in the heavy chain variable region of anti-DNA antibodies from lupus-prone (NZB/NZW F1) mice.

65 tibodies >/=1:80 and/or anti-double-stranded DNA antibodies >/=30 IU/ml) at baseline was retrospectiv

66 to be correlated to the Arg content of anti-DNA antibody hypervariable loops.

67 tion of 1:120 or more), anti-double-stranded DNA antibodies in 55 percent, anti-Ro antibodies in 47 p

68 as sufficient to induce anti-double-stranded DNA antibodies in a murine model of drug-induced lupus,

69 ed in prompt production of IgM antidenatured DNA antibodies in C57BL/6xDBA/2 F1 mice.

70 creases in median levels of anti-PS and anti-DNA antibodies in children with SM compared to CC (p < 0

71 y to quantify over the course of 30 min anti-DNA antibodies in fresh human serum without background r

72 ower concentrations of DNA complexed to anti-DNA antibodies in human serum, we found a maximal enhanc

73 vels of all immunoglobulin isotypes and anti-DNA antibodies in serum.

74 Deposition of anti-DNA antibodies in the kidney contributes to the pathogen

75 ominance, appearance of anti-double-stranded DNA antibodies in young adulthood, intravascular deposit

76 asma C4d, Bb, C5b-9 and anti-double-stranded DNA antibody in distinguishing patients with from those

77 eled antibody to evaluate deposition of anti-DNA antibody in the kidney and the successful use of a p

78 s mice from renal deposition of the R4A anti-DNA antibody in vivo.

79 d mice express high-affinity, unmutated anti-DNA antibodies, indicating that naive B cells that are n

80 that treatment of mesangial cells with anti-DNA antibodies induced high expression of neutrophil gel

81 g of the single chain Fv fragment of an anti-DNA antibody known to penetrate into living cells and ti

82 r patients with RA, 92% used either the anti-DNA antibody level or complement C3 level to monitor pat

83 mponent C3 and elevated anti-double-stranded DNA antibody levels at baseline improved in some, but no

84 Because anti-DNA antibody levels can reflect disease activity, repeat

85 asured anti-phosphatidylserine (PS) and anti-DNA antibody levels in 382 Ugandan children prospectivel

86 we continue to rely on anti-double-stranded DNA antibody levels to assess serologic activity.

87 counts, Ig levels, and anti-double-stranded DNA antibody levels were available as part of the clinic

88 m IgG antichromatin and anti-double-stranded DNA antibody levels were lower in NZM.Baff(-/-) .April(-

89 tibody-producing B cells, reduced serum anti-DNA antibody levels, retarded the development of nephrit

90 k this study to determine if pathogenic anti-DNA antibodies may also contribute to renal damage by di

91 ndicate that the renal pathogenicity of anti-DNA antibodies may be attributed in part to their abilit

92 uggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and b

93 Our findings indicate that anti-DNA antibodies may promote important neuropathologic mec

94 The mechanism by which anti-DNA antibodies mediate lupus nephritis has yet to be con

95 s and the production of high titer ss and ds DNA antibodies of the IgG subclass that are not normally

96 Anti-DNA antibodies often play an important role in disease p

97 fluorescently stained eDNA with either anti-DNA antibodies or an ultrasensitive cell-impermeant dye,

98 reduce serum levels of anti-double-stranded DNA antibodies or renal immune complexes but did decreas

99 G anti-chromatin and/or anti-double-stranded DNA antibodies or with amounts of these autoantibodies d

100 test results were identified with respect to DNA antibody or C3 levels.

101 Specifically, no patient developed anti-DNA antibody or muscle enzyme elevations.

102 no changes in serum levels of IgG, IgG anti-DNA antibodies, or V(H)4-34 antibodies during the study.

103 ciated with anti-Ro and anti-double-stranded DNA antibodies (P = 4.6 x 10(-18) and P = 2.9 x 10(-16)

104 The structural underpinnings of anti-DNA antibody pathogenicity and antibody-DNA recognition,

105 Anti-DNA antibodies play important roles in the pathogenesis

106 ion of TLS was found in anti-double-stranded DNA antibody-positive mice, and the structures were orga

107 ly reduced the frequency of IgG and IgG anti-DNA antibody-producing B cells, and these changes persis

108 opes induced CD8(+) T cells that killed anti-DNA antibody-producing B cells, reduced serum anti-DNA a

109 NZW F1 mice and evaluated the effect on anti-DNA antibody-producing B cells.

110 ed key disease manifestations including anti-DNA antibody production and glomerulonephritis.

111 nucleic acids stimulates interferon and anti-DNA antibody production in SLE.

112 plexes and autoreactive T-cell help for anti-DNA antibody production suggest novel directions for the

113 nors induced lupus with anti-double stranded DNA antibodies, proteinuria, and immune complex glomerul

114 vels of anti-Scl-70 and anti-double-stranded DNA antibodies (r = 0.558, P < 0.001).

115 y to a hybridized 76-base tag DNA with a tag DNA/antibody ratio of 50:1.

116 e compared with previously published data on DNA-antibody recognition.

117 uble-check its selectivity, two specific RNA-DNA antibodies recognizing miRNA-DNA heteroduplexes, ant

118 Anti-double stranded (ds) DNA antibodies represent a pathogenic autospecificity in

119 and its levels inversely correlate with anti-DNA antibody response.

120 algia and fever did not relapse, and anti-ds DNA antibody returned to normal during a follow-up perio

121 increase in the number of high-affinity anti-DNA antibody-secreting B cells in the spleens of E(2)-tr

122 treatment, and the frequency of Ig and anti-DNA antibody-secreting B cells was analyzed by enzyme-li

123 f 3 patients, and a 10-fold decrease in anti-DNA antibody-secreting cell lines was found after treatm

124 antibody with no DNA binding capability, and DNA antibody simultaneously with blocking peptide.

125 ental parameters such as the amount of input DNA, antibody specificity, ChIP enrichment and sequencin

126 creening strategies now involve ANA and anti-DNA antibody testing to identify patients with so-called

127 une liver disease and greater titers of anti-DNA antibodies than did males, and 2-7 times more cells

128 nd had higher titers of anti-double-stranded DNA antibodies than wild-type MRL/lpr mice.

129 ignificantly higher renal deposition of anti-DNA antibody than of antibody without DNA binding capabi

130 as anti-nuclear and anti-double-stranded (ds)DNA antibodies that are characteristic of SLE.

131 cept, we address a problem of detecting anti-DNA antibodies that are characteristic of systemic lupus

132 ixed TCDM also reduced the formation of anti-DNA antibodies that are observed typically in male mice

133 SLE patients produce anti-DNA antibodies that crossreact with NMDA receptors and a

134 ed TCDM also prevented the formation of anti-DNA antibodies that is typically observed in male mice o

135 heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for dsDNA does not a

136 with R4A, a pathogenic mouse monoclonal anti-DNA antibody that deposits in glomeruli.

137 related positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumato

138 (P < 0.0001) and median anti-double-stranded DNA antibody titers from 106 to 42 IU/ml (P < 0.0001), a

139 D resulted in increased anti-double-stranded DNA antibody titers in lupus-prone mice.

140 e presence of proteinuria, hypertension, and DNA antibody titers were reviewed with respect to diseas

141 gene-expressing B cells, elevated serum anti-DNA antibody titers, and glomerular immunoglobulin depos

142 ssociated with enhanced anti-double-stranded-DNA antibody titers.

143 ced atherosclerosis and anti-double-stranded DNA antibody titers.

144 lupus erythematosus, recent studies of anti-DNA antibody transgenic mice clearly demonstrate that an

145 A one-unit increase in anti-DNA antibodies was associated with a 2.99 (95% CI, 1.68,

146 Positivity for anti-double-stranded DNA antibodies was associated with the expression levels

147 riation in the level of anti-double-stranded DNA antibody was different in individual patients.

148 ddress these issues for anti-single-stranded DNA antibodies, we have determined the 2.1 A crystal str

149 Increases in anti-PS and anti-DNA antibodies were associated with decreased hemoglobin

150 Elevated anti-PS and anti-DNA antibodies were associated with post-discharge morta

151 Anti-double-stranded DNA antibodies were associated with renal disease and ap

152 compared with (+/+) mice, but levels of anti-DNA antibodies were comparable in all groups.

153 Accordingly, anti-double-stranded DNA antibodies were elevated in patients with symptomati

154 y inhibitor were injected into mice and anti-DNA antibodies were measured by enzyme-linked immunosorb

155 and CH50 and titers of anti-double-stranded DNA antibodies were normalized after treatment with eith

156 t triggers the formation of IgG anti-histone/DNA antibodies, when expressed on the B6 background as a

157 Moreover, anti-DNA antibodies with this cross-reactivity mediate apopto

158 Anti-double-stranded DNA antibodies, with a mean onset 2.2 years before the d